PRESS RELEASES:
Tampere, FINLAND Feb 6th, 2025: VidaNomi Opens €2M Seed Round to Revolutionize Colorectal Cancer Screening with AI-Powered Smart Pill
VidaNomi, a deep-tech health startup pioneering AI-driven smart pill technology for colorectal cancer detection, has officially launched its €2 million seed funding round. This round will accelerate clinical trials, regulatory approvals, and go-to-market preparation for its non-invasive, wireless endoscopy solution, addressing an €18 billion market at the intersection of AI diagnostics, smart pills, and preventative healthcare.
A Global Health Crisis Needs a Scalable, AI-Powered Solution
Colorectal cancer is the second deadliest cancer worldwide, yet 90% of cases could be prevented with early detection. However, traditional screening methods, colonoscopy and capsule endoscopy, are either invasive, costly, or inefficient, resulting in low participation rates and late diagnoses.
VidaNomi’s AI-powered smart pill is designed to eliminate these barriers by offering:
✅ 100% gastrointestinal coverage with wireless power and data transfer.
✅ Automated real-time AI analysis, reducing dependency on manual interpretation.
✅ At-home usability, significantly increasing early screening adoption.
✅ Projected 30–50% cost savings for healthcare systems by optimizing detection and treatment.
✅ 100% gastrointestinal coverage with wireless power and data transfer.
✅ Automated real-time AI analysis, reducing dependency on manual interpretation.
✅ At-home usability, significantly increasing early screening adoption.
✅ Projected 30–50% cost savings for healthcare systems by optimizing detection and treatment.
"The future of colorectal cancer screening is AI-driven, automated, and accessible," says Dr. Fahad Sohrab, CEO of VidaNomi. "VidaNomi is not just a medical device—it’s a paradigm shift in preventative healthcare. With this funding round, we are moving from advanced prototyping to clinical validation, bringing a life-saving solution to a market ready for disruption."
Investment Opportunity
Round Size: €2 million (Seed Round)
Use of Funds:
✅ Final prototype development & AI refinement
✅ Regulatory approvals (FDA & CE MDR pre-submission)
✅ Preclinical & early human trials
✅ Expanding R&D and strategic partnerships
✅ Regulatory approvals (FDA & CE MDR pre-submission)
✅ Preclinical & early human trials
✅ Expanding R&D and strategic partnerships
Market Timing:
✅ AI-driven diagnostics market growing at 24.6% CAGR
✅ €15B colorectal diagnostics market primed for disruption
✅ €15B colorectal diagnostics market primed for disruption
VidaNomi offers:
✅ Category-defining technology: A first-of-its-kind AI-powered smart pill for at-home use
✅ Strong IP & market differentiation: Wireless power + full GI analysis
✅ Multiple exit pathways: High acquisition potential by medtech leaders, highly scalable product and growing market
✅ Strong IP & market differentiation: Wireless power + full GI analysis
✅ Multiple exit pathways: High acquisition potential by medtech leaders, highly scalable product and growing market
Join the Movement
VidaNomi is actively engaging with investors, healthcare partners, and industry leaders who share its mission: to eliminate late-stage colorectal cancer through cutting-edge technology.
About VidaNomi
VidaNomi is an AI-powered smart pill & analytics platform designed to revolutionize colorectal cancer screening. By combining non-invasive diagnostics, AI-driven anomaly detection, and real-time wireless data transmission, VidaNomi aims to redefine preventative healthcare while drastically reducing costs and mortality rates.
VidaNomi is an AI-powered smart pill & analytics platform designed to revolutionize colorectal cancer screening. By combining non-invasive diagnostics, AI-driven anomaly detection, and real-time wireless data transmission, VidaNomi aims to redefine preventative healthcare while drastically reducing costs and mortality rates.
Tampere, FINLAND Jan 23rdth, 2025: VidaNomi Joins the Dock Program at Platform 6 in Tampere
VidaNomi, the innovative smart pill company focused on gastrointestinal health, is proud to join the Dock program at Platform 6 in Tampere. This opportunity will allow VidaNomi to collaborate with experts and expand its network, supporting the growth of its smart pill technology for better patient care.
Through the Dock program, VidaNomi aims to strengthen its presence in the healthcare sector and accelerate the development of non-invasive diagnostic solutions for GI disorders.
More information: vidanomi@iine.studio
Logos for press use (right click to save):
